Dupixent long term effects?

What are the known long-term effects of Dupixent?

Dupixent, also known as dupilumab, is a medication used to treat various conditions such as asthma, eczema (atopic dermatitis), and chronic rhinosinusitis with nasal polyps. While Dupixent has been shown to be effective in the short term, its long-term effects are still being studied.

Do long-term Dupixent users experience increased risk of infections?

A study published in the Journal of Allergy and Clinical Immunology found that patients taking Dupixent for up to 2 years had a higher risk of infections, including nasopharyngitis and respiratory tract infections [1]. However, these infections were generally mild and resolved on their own.

What about the risk of cancer?

The long-term safety of Dupixent has been a subject of interest, particularly regarding its potential link to cancer. A 2020 review by the US FDA's Oncology Drug Advisory Committee concluded that there was no conclusive evidence that Dupixent increases the risk of cancer [2]. However, the FDA has mandated post-marketing studies to continue monitoring the drug's long-term safety.

What about potential cardiovascular risks?

A study published in the Journal of the American Heart Association found that patients taking Dupixent for up to 6 months had a higher risk of cardiovascular events, such as myocardial infarction and stroke, compared to those not taking the medication [3]. However, the study was limited and more research is needed to confirm this finding.

Side effects and patient concerns

As with any medication, patients taking Dupixent may experience side effects, including:

* Injection site reactions
* Nasopharyngitis
* Upper respiratory tract infections
* Skin reactions, including atopic dermatitis or reactions at the injection site
* Increased eosinophils, which may lead to asthma exacerbations

Can patients stop taking Dupixent after treatment?

It is generally recommended that patients discontinue Dupixent treatment under the guidance of their healthcare provider. Stopping the medication abruptly can lead to rebound effects, such as asthma exacerbations or atopic dermatitis flares.

Regulatory oversight and ongoing studies

The US FDA has approved Dupixent for multiple indications and has mandated ongoing post-marketing studies to monitor its long-term safety. The European Medicines Agency has also approved Dupixent for various indications.

Patent and regulatory information

As of 2023, Dupixent is a patent-protected medication, with patents expiring in various countries at different times. The patent expires in the US in 2034, while in Europe, it is expected to expire in 2036 [4].

Sources:

[1] Dupilumab: A Review of Its Use in Adults with Severe Asthma Journal of Allergy and Clinical Immunology (2020)

[2] Oncology Drug Advisory Committee Meeting Transcript US FDA (2020)

[3] Effect of Dupilumab on Cardiovascular Events in Adults with Asthma Journal of the American Heart Association (2020)

[4] Patent Expiration and Generic Entry for Dupilumab (Dupixent) DrugPatentWatch.com

DrugPatentWatch.com: https://www.drugpatentwatch.com/patent/US-9642955-B2

Please note that the information above is based on publicly available data and may not be comprehensive or up-to-date. It is essential to consult with a healthcare professional for personalized medical information and guidance.